Recurrence-Free Long-Term Survival After Liver Transplantation in Patients with 18F-FDG Non-Avid Hilar Cholangiocarcinoma on PET
| Autor: | Dietmar Gottschild, K. Thrum, A. Sappler, A. Kornberg, J. Wilberg, B. Küpper |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Adult
Male medicine.medical_specialty medicine.medical_treatment Population Liver transplantation Gastroenterology Disease-Free Survival Bile duct cancer Cholangiocarcinoma Fluorodeoxyglucose F18 Risk Factors Internal medicine medicine Humans Immunology and Allergy Pharmacology (medical) education Survival rate Aged Retrospective Studies Transplantation education.field_of_study medicine.diagnostic_test business.industry Cancer Middle Aged medicine.disease Liver Transplantation Survival Rate Klatskin tumor Bile Ducts Intrahepatic Bile Duct Neoplasms Positron emission tomography Positron-Emission Tomography Female Neoplasm Recurrence Local business Nuclear medicine Liver cancer |
| Zdroj: | American Journal of Transplantation. 9:2631-2636 |
| ISSN: | 1600-6135 |
| Popis: | The aim of this retrospective study was to assess the value of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) for predicting biological tumor behavior and outcome after liver transplantation (LT) in patients with otherwise unresectable hilar cholangiocarcinoma (HC). Preoperative (18)F-FDG-PET scanning was performed in 13 patients with type IV Klatskin tumor before LT. PET+ status indicated patients with an increased pretransplant (18)F-FDG uptake, whereas PET- recipients had no increased preoperative (18)F-FDG uptake on PET. Pretransplant PET findings were correlated with histopathological tumor characteristics and patient outcome after LT. Eight patients demonstrated positive preoperative PET findings (61.5%), whereas five patients had no increased preoperative (18)F-FDG tumor uptake (38.5%) on PET. One PET+ patient died after 1 month due to liver allograft dysfunction. Seven PET+ liver recipients developed tumor recurrence, whereas five PET- patients were tumor-free alive after a median of 76 months post-LT (p = 0.001). The 2-year recurrence-free survival rate after LT was 100% in PET- patients and 28.6% in the PET+ population (log-rank = 0.008). Our results suggest that patients with (18)F-FDG non-avid HC on PET may achieve recurrence-free long-term survival after LT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text